Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Lanzillo

Showing results (181-190 of 210) with videos related to

Pageof 21
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 23, 2023
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)Clara G Chisari, Assunta Bianco, Vincenzo Brescia Morra, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 15, 2024
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian studyCaterina Lapucci, Jessica Frau, Eleonora Cocco, et al.
Multiple Sclerosis and Related Disorders|October 15, 2019
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disordersGiovanni Novi, Francesca Bovis, Marco Capobianco, et al.
Journal of Neurology|November 3, 2023
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster doseMassimiliano Di Filippo, Diana Ferraro, Paolo Ragonese, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 28, 2019
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?Marinella Clerico, Stefania Federica De Mercanti, Alessio Signori, et al.
Immunity|May 18, 2021
Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potentialClaudio Procaccini, Silvia Garavelli, Fortunata Carbone, et al.
Journal of Neurology|March 18, 2018
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT studyRoberta Lanzillo, Luca Prosperini, Claudio Gasperini, et al.
Journal of the Neurological Sciences|March 26, 2021
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian studyStefania Federica De Mercanti, Alessio Signori, Cinzia Cordioli, et al.
Multiple Sclerosis and Related Disorders|November 4, 2019
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre studyDiana Ferraro, Pietro Annovazzi, Marcello Moccia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 23, 2022
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapiesIrene Schiavetti, Cinzia Cordioli, Maria Laura Stromillo, et al.
Pageof 21

Showing results (181-190 of 210) with videos related to

Sort By:
Pageof 21
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 23, 2023
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)Clara G Chisari, Assunta Bianco, Vincenzo Brescia Morra, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 15, 2024
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian studyCaterina Lapucci, Jessica Frau, Eleonora Cocco, et al.
Multiple Sclerosis and Related Disorders|October 15, 2019
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disordersGiovanni Novi, Francesca Bovis, Marco Capobianco, et al.
Journal of Neurology|November 3, 2023
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster doseMassimiliano Di Filippo, Diana Ferraro, Paolo Ragonese, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 28, 2019
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?Marinella Clerico, Stefania Federica De Mercanti, Alessio Signori, et al.
Immunity|May 18, 2021
Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potentialClaudio Procaccini, Silvia Garavelli, Fortunata Carbone, et al.
Journal of Neurology|March 18, 2018
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT studyRoberta Lanzillo, Luca Prosperini, Claudio Gasperini, et al.
Journal of the Neurological Sciences|March 26, 2021
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian studyStefania Federica De Mercanti, Alessio Signori, Cinzia Cordioli, et al.
Multiple Sclerosis and Related Disorders|November 4, 2019
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre studyDiana Ferraro, Pietro Annovazzi, Marcello Moccia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 23, 2022
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapiesIrene Schiavetti, Cinzia Cordioli, Maria Laura Stromillo, et al.
Pageof 21